Core Viewpoint - The company emphasizes its commitment to core business operations and strategic acquisitions, aiming for synergy and collaboration with high-quality targets in the future [1] Group 1: Business Strategy - The company will continue to pursue mergers and acquisitions that align with its core business and create synergistic effects [1] - There is no current plan for a Hong Kong stock listing, but the company will evaluate this based on business development and market conditions [1] Group 2: Financial Position - The company's financial situation is manageable, supporting existing research and business needs [1] - If the funding requirements for innovative drug projects increase in the later stages, the company may consider refinancing options [1] Group 3: Stock Market Operations - The company has been included in the Shanghai-Hong Kong Stock Connect, which will help optimize its equity structure and enhance stock liquidity [1]

证券日报网12月25日讯，联环药业（600513）在接受投资者提问时表示，公司高度重视员工激励与人才 保留，已建立差异化的薪酬体系，研发人员薪酬与项目进展深度挂钩，将研发流程分阶段给予团队相应 奖励，充分调动创新积极性。此外，公司已连续多年为员工调资，让员工切实共享企业发展的成果。公 司将进一步完善激励机制，吸引更多优秀人才投身研发与创新业务。 ...

证券日报网讯 12月25日，富祥药业（300497）发布公告称，截至本公告日，公司尚在有效期内累计担 保总额度为12.29亿元，均为全资子公司及控股子公司担保。公司累计对外担保总额度占公司最近一期 经审计净资产的比例为56.36%，实际已发生的有效对外担保总余额为7.515亿元（含本次新增使用担保 额度），占公司最近一期经审计净资产的比例为34.47%。公司无逾期对外担保，无涉及诉讼的对外担 保及因担保被判决败诉而应承担损失的情形。 ...

| NORTHER THE VEY | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | | 奥出营业部 | 是否为专场 | | 025-12-25 | 恒瑞医药 | 600276 | 2271.8 61.4 37 | 我們都會隨著點 | 我們都會隨 | Ki | 12月25日，恒瑞医药大宗交易成交37万股，成交额2271.8万元，占当日总成交额的2.33%，成交价61.4 元，较市场收盘价61.4元持平。 ...

Market Overview - The chemical pharmaceutical sector increased by 0.26% on December 25, with Hongyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] Top Performers - Hongyuan Pharmaceutical (301246) closed at 22.40, up 7.74%, with a trading volume of 392,500 shares and a transaction value of 825 million [1] - Shanghai Yizhong (688091) closed at 48.82, up 4.34%, with a trading volume of 45,600 shares and a transaction value of 220 million [1] - Yiduoli (300381) closed at 6.72, up 3.70%, with a trading volume of 121,500 shares and a transaction value of 80.94 million [1] Underperformers - Tuisu Suwu (600200) closed at 0.31, down 6.06%, with a trading volume of 301,300 shares and a transaction value of 9.64 million [2] - Kangla Pharmaceutical (300086) closed at 12.78, down 3.98%, with a trading volume of 937,200 shares and a transaction value of 1.224 billion [2] - Baile Tianheng (688506) closed at 331.00, down 3.22%, with a trading volume of 10,700 shares and a transaction value of 359 million [2] Capital Flow - The chemical pharmaceutical sector experienced a net outflow of 1.089 billion from institutional investors, while retail investors saw a net inflow of 1.084 billion [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional selling contrasted by retail buying [2] Individual Stock Capital Flow - Hongyuan Pharmaceutical saw a net inflow of 132.15 million from retail investors, while institutional investors had a net outflow of 50.77 million [3] - Shanghai Yizhong had a net inflow of 19.13 million from institutional investors, while retail investors experienced a net outflow of 1.68 million [3] - Yiduoli had a net inflow of 26.80 million from institutional investors, while retail investors had a net outflow of 23.79 million [3]

Core Viewpoint - The company, Borui Pharmaceutical (688166.SH), announced that the interest payment for its convertible bonds issued on January 4, 2022, will commence on January 5, 2026, due to January 4, 2026, being a non-trading day [1] Group 1 - The interest payment marks the fourth year of interest for the "Borui Convertible Bonds" [1] - The interest accrual period is from January 4, 2025, to January 3, 2026 [1] - The coupon rate for this interest year is set at 1.5% (tax included), resulting in an interest payment of 15 RMB (tax included) for each bond with a face value of 1,000 RMB [1]

Core Viewpoint - TuoXin Pharmaceutical (301089.SZ) announced that its wholly-owned subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd. (referred to as "Jingquan Biotechnology"), has received a Food Production License from the Henan Provincial Market Supervision Administration, allowing for the production of three new food additive products [1] Group 1 - Jingquan Biotechnology's license change includes the addition of production qualifications for three new products: 2-oxopentanoic acid, L-citrulline, and 4-aminobutyric acid (also known as γ-aminobutyric acid) [1]

Group 1 - The company has initiated trial production for its VC project, indicating progress in its development phase [1] - The company acknowledges that it still needs to undergo a capacity ramp-up process, which is a critical step before full-scale production can be achieved [1]

Group 1 - Guangqi Technology's controlling shareholder proposed a share buyback of 50 million to 100 million yuan for employee stock ownership plans or equity incentives [1] - Xingyuan Zhuomai received a supplier designation from a domestic electric vehicle manufacturer to develop and supply reducer shell components, with expected sales of approximately 575 million yuan over four years from 2027 to 2030 [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Hongda Electronics disclosed uncertainty regarding the IPO progress of its associate Jiangsu Zhanxin, in which it holds a 13.79% stake [4] - Kangchen Pharmaceutical received FDA approval to conduct clinical trials for its KC1086 project, aimed at treating advanced recurrent or metastatic solid tumors [5] - Kweichow Moutai adjusted its share buyback price ceiling to 1863.67 yuan per share, effective from December 19, 2025 [6] Group 3 - Mousse Co. announced that its controlling shareholder and actual controllers committed not to reduce their holdings within one year [7] - Tongxingbao's subsidiary signed a business contract worth 43.166 million yuan for a cloud expansion project [8] - Kaifa Electric announced plans for three shareholders to collectively reduce their holdings by 0.6999% [9] Group 4 - Longpan Technology plans to increase the production capacity of lithium iron phosphate cathode materials from 62,500 tons per year to 100,000 tons per year [10] - Zhuhai Guanyu announced plans for two shareholders to reduce their holdings by up to 3% [11] - Jiaheng Home Textiles is planning a change in control, leading to a temporary suspension of its stock [12] Group 5 - Kehua Bio's subsidiary received a medical device registration certificate for a gene polymorphism detection kit [13] - Saitex New Materials' actual controller plans to reduce holdings by up to 3% [14] - Sanhui Electric announced a shareholder's plan to reduce holdings by up to 2% [15] Group 6 - Binhua Co. plans to establish a venture capital fund with a total scale of 400 million yuan, focusing on strategic emerging industries [16] - Jindun Co. announced plans for two shareholders to reduce their holdings by up to 4% [17] - Hengdian East Magnetic's controlling shareholder plans to reduce holdings by up to 1% [18][19] Group 7 - Luxin Investment's controlling shareholder plans to reduce holdings by up to 1% [20] - Huakang Clean announced a joint bid for a hospital procurement project worth 157 million yuan [21] - Xuedilong plans to reduce its repurchased shares by up to 488,560 shares [22] Group 8 - Enhua Pharmaceutical's subsidiary signed an exclusive commercial cooperation agreement for three long-acting antipsychotic products [23] - Aier Eye Hospital plans to acquire partial equity in 39 institutions for a total of 963 million yuan [24] - Gaozheng Mining plans to acquire 100% equity of Overseas Explosives for 510 million yuan [25] Group 9 - Donghong Co. plans to repurchase shares worth 30 million to 60 million yuan for employee stock ownership plans [26] - Bear Electric's controlling shareholder plans to reduce holdings by up to 0.64% [27] - *ST Zhengping announced the initiation of pre-restructuring by the Xining Intermediate Court [28][29] Group 10 - Caesar Travel's shareholder plans to reduce holdings by up to 3% [30] - Lianchuang Electronics announced a change in controlling shareholder to Jiangxi State-owned Assets Supervision and Administration Commission [31] - Beixin Road and Bridge plans to transfer 5.33% equity in Henan Yuhang for 243 million yuan [32] Group 11 - Fenglong Co. is planning a change in control, with stock resuming trading [33]

Group 1 - The core viewpoint of the news is that Chengda Pharmaceutical's stock performance and financial metrics indicate a mixed outlook, with significant financing activity and a notable decline in net profit despite revenue growth [1][2]. Group 2 - On December 24, Chengda Pharmaceutical's stock fell by 0.86%, with a trading volume of 151 million yuan. The financing buy-in amount for the day was 18.04 million yuan, while the financing repayment was 12.14 million yuan, resulting in a net financing buy of 5.90 million yuan. The total financing and securities balance reached 263 million yuan [1]. - The financing balance of Chengda Pharmaceutical is 263 million yuan, accounting for 4.11% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of financing activity [1]. - As of December 24, there were no shares repaid or sold in the securities lending market, with a securities lending balance of 0 yuan, which is also at a high level compared to the past year [1]. Group 3 - As of September 30, the number of shareholders for Chengda Pharmaceutical was 12,700, a decrease of 8.58% from the previous period. The average circulating shares per person increased by 36.16% to 8,577 shares [2]. - For the period from January to September 2025, Chengda Pharmaceutical achieved operating revenue of 285 million yuan, representing a year-on-year growth of 16.95%. However, the net profit attributable to the parent company was 16.77 million yuan, a decrease of 58.47% year-on-year [2]. Group 4 - Chengda Pharmaceutical has distributed a total of 133 million yuan in dividends since its A-share listing, with cumulative distributions of 89.62 million yuan over the past three years [3].